Establishment and Comprehensive Characterization of a Novel Preclinical Platform of Metastatic Retinoblastoma for Therapeutic Developments.
Zugbi S, Aschero R, Ganiewich D, Cancela MB, Winter U, Ottaviani D, Sampor C, Dinardi M, Torbidoni AV, Mena M, Balaguer-Lluna L, Lamas G, Sgroi M, Lagomarsino E, Lubieniecki F, Fandiño A, Radvanyi F, Abramson DH, Podhajcer O, Llera AS, Cafferata EG, Chantada G, Carcaboso AM, Schaiquevich P.
Zugbi S, et al. Among authors: mena m.
Invest Ophthalmol Vis Sci. 2023 Dec 1;64(15):27. doi: 10.1167/iovs.64.15.27.
Invest Ophthalmol Vis Sci. 2023.
PMID: 38117242
Free PMC article.
PURPOSE: Although there have been improvements in the management of metastatic retinoblastoma, most patients do not survive, and all patients suffer from multiple short- and long-term treatment toxicities. Reliable and informative models to assist clinicians are needed. .. …
PURPOSE: Although there have been improvements in the management of metastatic retinoblastoma, most patients do not survive, and all patient …